About this Research Topic
Lung cancer is a prevalent malignant tumor worldwide and the most common cause of cancer-related mortality, resulting in nearly 1.8 million deaths each year. Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, accounting for approximately 85% of all lung cancer cases.
In the past decades, with the development of genomics and histology, the diagnosis and treatment of lung cancer have been greatly revolutionized. An increasing number of monoclonal antibodies and small molecular inhibitors have been developed to specifically target the cancer driver genes or their downstream signaling pathways, showing higher potent and fewer side effects in the treatment of NSCLC compared to traditional radiotherapy and chemotherapy. While targeted therapies have dramatically improved outcomes in advanced NSCLC patients harboring oncogenic driver mutations, acquired resistance invariably develops within the first or two years after initial treatment. In addition, a subset of patients have no treatment response to the initial targeted therapies. The mechanisms of response and resistance to targeted therapies in NSCLC patients are still not fully elucidated.
Therefore, this Research Topic aims to gain new insights into the treatment response and resistance to targeted therapies for NSCLC. We welcome researchers to submit Original Research, Review, and Case Report articles focusing on:
1. mechanisms of early treatment response to targeted therapies for NSCLC
2. mechanisms of acquired resistance to targeted therapies for NSCLC
3. strategies to delay and overcome resistance to targeted therapies for NSCLC
In the past decades, with the development of genomics and histology, the diagnosis and treatment of lung cancer have been greatly revolutionized. An increasing number of monoclonal antibodies and small molecular inhibitors have been developed to specifically target the cancer driver genes or their downstream signaling pathways, showing higher potent and fewer side effects in the treatment of NSCLC compared to traditional radiotherapy and chemotherapy. While targeted therapies have dramatically improved outcomes in advanced NSCLC patients harboring oncogenic driver mutations, acquired resistance invariably develops within the first or two years after initial treatment. In addition, a subset of patients have no treatment response to the initial targeted therapies. The mechanisms of response and resistance to targeted therapies in NSCLC patients are still not fully elucidated.
Therefore, this Research Topic aims to gain new insights into the treatment response and resistance to targeted therapies for NSCLC. We welcome researchers to submit Original Research, Review, and Case Report articles focusing on:
1. mechanisms of early treatment response to targeted therapies for NSCLC
2. mechanisms of acquired resistance to targeted therapies for NSCLC
3. strategies to delay and overcome resistance to targeted therapies for NSCLC
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
